Recruiting studies: Immunoglobulin G4 Related Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

National Registry of IgG4-RD in China
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT03023371 Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Phase 1/Phase 2 · 3 location(s) · Acepodia Biotech, Inc. · NCT07061938 Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
Phase N/A · 2 location(s) · Military Medical Clinical Center of the Southern Region, Ukr · NCT07536841 A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647 Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497361 Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
Phase N/A · 1 location(s) · Universidad Politecnica de Madrid · NCT05681975 A Prospective Cohort Study of IgG4RD in China
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT01670695 A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
Phase 2/Phase 3 · 1 location(s) · Peking Union Medical College Hospital · NCT07068165 Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497387 Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07148791 The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Com
Phase 2/Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT07535554 Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Phase 2 · 6 location(s) · UMC Utrecht · NCT06285539 Short-term Glucocorticoid Combined with MMF for IgG4-RD
NA · 1 location(s) · Wen Zhang · NCT06663618 Meir Medical Center Rheumatologic Biobank
Phase N/A · 1 location(s) · Meir Medical Center · NCT03473912 AYLo - AutoimmunitY and Loss of y
Phase N/A · 1 location(s) · University of Bonn · NCT06696027 the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT07339540 A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
NA · 1 location(s) · Luo Yaping · NCT07104058 The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Phase 1 · 1 location(s) · Nanjing University School of Medicine · NCT06285279 Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05789030 BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06794008 Institutional Registry of Rare Diseases
Phase N/A · 1 location(s) · Hospital Italiano de Buenos Aires · NCT06573723 A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Phase 3 · 79 location(s) · Sanofi · NCT07190196

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.